Kite Pharma, Inc. Insider Trading for May 2017
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in Kite Pharma, Inc..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of insider trading in Kite Pharma, Inc. for May 2017.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| May 11 2017 | KITE | Kite Pharma, Inc. | Nussbaum Ran | Director | Buy | P | 68.94 | 2,632 | 181,450 | 2,632 | 0 to 2.6 K |
| May 11 2017 | KITE | Kite Pharma, Inc. | Nussbaum Ran | Director | Buy | P | 69.17 | 1,029 | 71,176 | 1,029 | 0 to 1 K |
| May 11 2017 | KITE | Kite Pharma, Inc. | Nussbaum Ran | Director | Buy | P | 69.17 | 2,651 | 183,370 | 2,651 | 0 to 2.7 K |
| May 11 2017 | KITE | Kite Pharma, Inc. | Nussbaum Ran | Director | Buy | P | 69.17 | 3,520 | 243,478 | 3,520 | 0 to 3.5 K |
| May 10 2017 | KITE | Kite Pharma, Inc. | JENKINSON PAUL L | Chief Financial Off ... | Buy | P | 72.59 | 3,000 | 217,770 | 3,000 | 0 to 3 K |
| May 10 2017 | KITE | Kite Pharma, Inc. | JENKINSON PAUL L | Chief Financial Off ... | Buy | P | 72.57 | 450 | 32,657 | 7,480 | 7 K to 7.5 K (+6.40 %) |
| May 10 2017 | KITE | Kite Pharma, Inc. | Ruchefsky Steven B | Director | Buy | P | 69.50 | 1,400 | 97,300 | 225,426 | 224 K to 225.4 K (+0.62 %) |
| May 09 2017 | KITE | Kite Pharma, Inc. | BONDERMAN DAVID | Director | Buy | P | 70.15 | 3,815 | 267,622 | 2,408,084 | 2.4 M to 2.4 M (+0.16 %) |
| May 09 2017 | KITE | Kite Pharma, Inc. | BONDERMAN DAVID | Director | Buy | P | 68.84 | 46,185 | 3,179,375 | 2,404,269 | 2.4 M to 2.4 M (+1.96 %) |
| May 09 2017 | KITE | Kite Pharma, Inc. | Belldegrun Arie | Chairman, President ... | Buy | P | 68.57 | 17,000 | 1,165,690 | 85,507 | 68.5 K to 85.5 K (+24.81 %) |
| May 03 2017 | KITE | Kite Pharma, Inc. | Kim Helen Susan | EVP, Business Devel ... | Option Exercise | M | 53.90 | 2,400 | 129,360 | 156,501 | |
| May 03 2017 | KITE | Kite Pharma, Inc. | Kim Helen Susan | EVP, Business Devel ... | Sell | S | 82.12 | 2,400 | 197,088 | 18,664 | 21.1 K to 18.7 K (-11.39 %) |
| May 03 2017 | KITE | Kite Pharma, Inc. | Kim Helen Susan | EVP, Business Devel ... | Buy | M | 53.90 | 2,400 | 129,360 | 21,064 | 18.7 K to 21.1 K (+12.86 %) |
| May 03 2017 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Option Exercise | M | 6.89 | 20,000 | 137,800 | 123,000 | |
| May 03 2017 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Sell | S | 83.36 | 300 | 25,008 | 50,165 | 50.5 K to 50.2 K (-0.59 %) |
| May 03 2017 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Sell | S | 82.60 | 5,905 | 487,753 | 50,465 | 56.4 K to 50.5 K (-10.48 %) |
| May 03 2017 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Sell | S | 81.84 | 13,795 | 1,128,983 | 56,370 | 70.2 K to 56.4 K (-19.66 %) |
| May 03 2017 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Buy | M | 6.89 | 20,000 | 137,800 | 70,165 | 50.2 K to 70.2 K (+39.87 %) |
| May 01 2017 | KITE | Kite Pharma, Inc. | CHAMPSI FARAH | Director | Sell | S | 82.59 | 2,617 | 216,138 | 4,962 | 7.6 K to 5 K (-34.53 %) |
| May 01 2017 | KITE | Kite Pharma, Inc. | CHAMPSI FARAH | Director | Sell | S | 82.77 | 16,551 | 1,369,926 | 7,579 | 24.1 K to 7.6 K (-68.59 %) |